Mineralocorticoid Receptor Antagonists in ESKD

descriptionPublicationkeyboard_double_arrow_right Article 08 Apr 2020 English Publisher:Ovid Technologies (Wolters Kluwer Health)Journal:Clinical Journal of the American Society of Nephrology, volume 15, pages 1,047-1,049 (issn: 1555-9041, eissn: 1555-905X,

Copyright policy )

Authors: Adhish, Agarwal; Alfred K, Cheung;

doi: 10.2215/cjn.13221019

pmid: 32269029

pmc: PMC7341785

Mineralocorticoid Receptor Antagonists in ESKD

- Summary
- Subjects
- Metrics

Abstract

There is an urgent need for interventions that reduce cardiovascular risks in patients with ESKD. Recently there has been considerable interest in whether blocking the effects of the mineralocorticoid aldosterone could be such an intervention. Since the 1980s, we have known that plasma aldosterone

Related Organizations

Huntsman Cancer Institute
United States
University of Utah
United States

Keywords

Cardiovascular Diseases, Humans, Kidney Failure, Chronic, Spironolactone, Aldosterone, Eplerenone, Mineralocorticoid Receptor Antagonists

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	9
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%